Aleksovski, Darko
Miljkovic, Dragana
Bravi, Daniele
Antonini, Angelo http://orcid.org/0000-0003-1040-2807
Funding for this research was provided by:
Horizon 2020 (643706)
Article History
Received: 3 July 2018
Accepted: 2 August 2018
First Online: 14 August 2018
Compliance with ethical standards
:
: This study was funded by EU Framework Programme for Research and Innovation Horizon 2020, under grant number 643706. Data used in the preparation of this article were obtained from the Parkinson’s Progression Markers Initiative (PPMI) database ( ExternalRef removed ).Angelo Antonini has received consultancy fees from AbbVie, Lundbeck and speaker honoraria from AbbVie, Boehringer Ingelheim, Sunovion, Lundbeck, Mundipharma, GE, UCB, Zambon, Ever Neuro Pharma, Movement Disorders Society. Daniele Bravi is an employee of Lundbeck. Darko Aleksovski and Dragana Miljkovic have no conflict of interest.